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The malignant cells of cutaneous T cell lymphoma (CTCL) display immunogenic
peptides derived from the clonal T cell receptor (TCR) providing an attractive model for
refinement of anti-tumor immunization methodology. To produce a clinically
meaningful anti-tumor response, induction of cytotoxic anti-CTCL cells must be
maximized while suppressive T regulatory cells (Treg) should be minimized. We have
demonstrated that engulfment of apoptotic CTCL cells by dendritic cells (DC) can lead to
either CD8 anti-CTCL responses or immunosuppressive Treg induction. Treg generation
is favored when the number of apoptotic cells available for ingestion is high. In this
study, we sought to determine whether the balance between immunity and
immunosuppression could be shifted towards a CD8 anti-CTCL response by lowering the
ratio of apoptotic CTCL cells available for DC ingestion. CTCL cell apoptosis was
produced by engagement of the TCR by anti-CD3 antibody affixed to magnetic beads.
The physical perturbation inherent in passage through a separation column induced
monocytes to differentiate into DC, demonstrated by increased expression of class II and
CD86 and decreased expression of the monocyte marker CD14. The immature DC
internalized and processed apoptotic CTCL cells and could potentially present the tumorderived peptides in the context of MHC class I and II. As the number of apoptotic cells
increased, there was a dose-dependent increase in the expression of Treg markers CTLA4, CD25, and FoxP3, with a ratio of apoptotic cell/DC loading of >10:1 corresponding to
the greatest Treg induction. These inducible phenotypic Treg also functionally inhibited
CD8-mediated perforin expression in vitro. At lower levels of apoptotic cell/DC loading
of <5:1, there was an expansion of the CD8 T cell compartment with increased perforin
expression and increased CTCL cell death, indicating anti-tumor activity. These
findings demonstrate that the ratio of apoptotic cells supplied to DC is an important
determinant of whether CD8 anti-tumor immunity or immunosuppression is generated.
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Introduction
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Historical Perspective
Cutaneous T cell lymphoma (CTCL) is an umbrella designation that unifies a diverse
group of clinical presentations on the basis of histopathologic and immunologic criteria.
CTCL, so named over thirty years ago to unite the diverse clinical presentations of
malignant CD4+ T cells that migrate to the skin [1], is now recognized as a clonal
proliferation of epidermotropic T cells that uniformly carry a common T cell receptor
(TCR) and also display cell surface expression of a memory (CD45RO+), inducer (CD4+),
and cutaneous homing leukocyte antigen (CLA+) phenotype [2-4].

Our initial understanding of the malignancy began in the early 1970’s, when researchers
discovered that Sezary syndrome, a known entity consisting of erythroderma and
abornmal circulating leukocytes with cerebriform nuclei, was in fact a proliferation of T
cells [5]. Following this discovery, work by Edelson et al demonstrated that the tissueinfiltrating lymphocytes of mycosis fungoides (MF), also a well known entity at the time,
were also of T cell origin [6]. The observation that these patients occasionally developed
into Sezary syndrome led to the notion that the two diseases may in fact be part of a
single spectrum of cutaneous lymphoma. Fast forward to today, and our understanding
has grown by leaps and bounds. The clonality of these malignant T cells has been
confirmed at the phenotypic and molecular level by the demonstration that the CTCL
cells all carry an identical TCR, and karyotype and polymerase chain reaction analysis
have revealed clonal abnormalities unique for individual patients [7-9]. Initially the
tumor cells localize in the skin of afflicted patients, surrounding Langerhans cells that
contribute to the CTCL cell growth [10]. As the disease progresses, the malignant cells
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become more poorly differentiated and often spread hematogenously throughout the body
as a leukemia, forecasting a much poorer prognosis. It is the early epidermal focus of
malignant T cells surrounding a central Langerhans cell [11], an immature member of the
dendritic cell (DC) series [12], that is the diagnostic hallmark of the disease, the Pautrier
microabscess [3], which is shown in Figure 1 [13].

Figure 1. Pautrier Microabscess

Clinical Presentation
CTCL can present in a variety of complex ways, from the classic patch or plaque lesions
associated with MF to the generalized erythema typically associated with Sezary
syndrome. In addition to the more common presentations, alternate ones may be seen as
well, including an eczematous form characterized by persistent, nonspecific, flat, red,
pruritic eczematous plaques and a tumor stage form, which develops from pre-existing
plaques or erythroderma. The more indolent forms of the disease are often so gradual in
onset that they are frequently misdiagnosed as atopic dermatitis or eczema for many
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years until a definitive diagnosis can be made [14]. Since the clinical presentation of the
malignancy depends upon the dominant subclone of the malignant T cell population
present, there tends to be a wide spectrum of clinical presentation. Given this variability
in presentation for cutaneous lymphoma, there are now two major classification systems
in use to help discern the many subtleties of the clinical nature of the malignancy [14].

Table 1. Classification of Cutaneous T Cell Lymphomas
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Histologic Diagnosis
Given the subtle and often insidious manner in which CTCL often presents, a diagnosis is
usually made through a combination of clinical, histologic, and immunologic criteria.
Biopsies should be taken from multiple lesions on the patient to ensure more accurate
diagnosis. Histologically, one can often recognize the classic Pautrier microabscess in a
certain cases, as shown in Figure 1, but more often can visualize lymphocytic infiltration
of the superficial dermis with individual migration of lymphocytes among keratinocytes.
This individual migration of atypical lymphocytes is characteristic of the
epidermotropism of the malignancy [13, 15]. As described earlier, the natural
progression of the malignancy involves progressive degrees of de-differentiation, which
leads to the eventual loss of the epidermotropism that was once characteristic of the
diseasee. Once the disease has sufficiently undifferentiated and has become leukemic,
diagnostic techniques can be expanded to include flow cytometric analysis of peripheral
blood to look for the clonal TCR Vβ family, increased CD4:CD8 T cell ratio, and loss of
the CD26 receptor [16-19]. Each of these techniques – clinical, histologic, and
immunologic – must be used in concert to make the most accurate diagnosis possible for
the malignancy.

Normal Immunology
While CTCL remains a relatively rare disorder, with the latest incidence rates of
approximately 0.36 per 100,000 person-years [20, 21], it remains an excellent model for
investigators interested in furthering their understanding of the mechanisms of immune
dysregulation. As a malignancy of CD4+ T cells, the study of this disease has allowed for
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the unique ability to investigate a malignancy of a prime player in the body’s immune
system. It has provided insight into the clinical manifestations of T cell dysfunction, and
has led to remarkable discoveries regarding the relationship between T cells and antigenpresenting cells of the immune system. These discoveries have had wide-reaching
effects and are applied to a number of other T cell mediated processes, including graftversus-host disease and psoriasis.

In normal human immunity, the skin serves as a first line of defense against the external
environment, protecting the body from chemical, microbial, and thermal agents, as well
as playing a key role in hydration status and maintenance of a constant body temperature.
Disruption of this vital organ can lead to serious consequences, including invasion by
environmental pathogens. The human immune system plays the most notable role in
protecting us from pathogenic invasion. Immunologically, this is accomplished through a
complex system of T cells and antigen-presenting cells/dendritic cells (APC/DC), which
are constantly circulating throughout the body. The role of the professional antigenpresenting cell is to phagocytose and process exogenous antigen and then present this
antigen to the TCR of circulating T cells. The T cell receptor is a complex of
heterodimeric proteins encoded by a set of four genes that recombine to form a diverse
population of circulating TCR [22]. This almost limitless population of diverse TCR
allows for the unique specificity that makes the adaptive immune response so effective.
As circulating naïve T cells circulate throughout the bloodstream, they encounter their
specific antigen presented on the surface of a mature dendritic cell. Mature DC that have
processed antigen are capable of migrating to lymph nodes where naïve T cells reside.
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Once the circulating T cells encounter antigen displayed in the context of MHC class I
and II in the peripheral lymphoid tissue, they proliferate and differentiate into antigenspecific effector cells [22, 23]. The presentation of antigen to naïve T cells is essential
for the generation of a T cell response, and is accomplished by the process and antigen
processing and presentation.

The effector cells of the immune system, T cells, are a population of leukocytes of the
adaptive immune system that are defined by their expression of either CD4 or CD8
accessory molecules. CD4+ T cells comprise the helper T cell subset and promote B cell
immunoglobulin production and can stimulate effector CD8+ T cell function [24, 25].
CD8+ T cells are stimulated by peptides displayed in class I MHC molecules on antigenpresenting cells and can mediate their tumor cytolysis through production of cytokines
such as TNF-α and the secretory granules perforin and granzymes [26].

Dendritic cells have assumed a central role in orchestrating both immunity and tolerance.
One key component of the type of immune response generated appears to be the
maturation status of the dendritic cell. Immature DC are aggressively phagocytic and
serve as sentinels, surveying the bloodstream for foreign invaders.[12, 27] Mature DC
up-regulate molecules that present antigen to the effectors cells of the immune system,
namely class I and II major histocompatibility antigens, and display co-stimulatory
molecules that enhance the immune response. [12] DC that present foreign peptides in
the context of high levels of co-stimulatory molecules such as CD80 and CD86 to naïve
and memory T cells promote both CD4 and CD8 T cell adaptive immunity. DC that
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present self peptide can induce T regulatory (Treg) cells and tolerance [28]. This
complex relationship between DC and presentation of antigen to naïve and memory T
cell is shown below.

Figure 3. Relationship between DC maturation status and induction of immunity or
tolerance.

T regulatory cells have been recently identified as CD4+, CD25+ T cells that inhibit
immune responses, prevent autoimmune disease, and maintain transplant tolerance [29,
30]. At least two types of Treg are currently recognized, those that are thymus-derived
and the circulating inducible Treg precursors that comprise 5-10% of the peripheral CD4
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T cell compartment [29]. There are a number of cell surface markers currently used to
characterize the Treg population, including the α-chain of the IL-2 receptor (CD25), the
inhibitory member of the co-stimulatory family cytotoxic T lymphocyte antigen-4
(CTLA-4), glucocorticoid-induced TNF receptor (GITR), and the forkhead transcription
factor, FoxP3. Treg cells are anergic and do not proliferate in response to TCR
stimulation [31, 32]. The mechanism of Treg cell suppression remains controversial and
appears to vary based on the culture conditions and the immunosuppression model
investigated [33]. Several models have described secretion of inhibitory cytokines as
well as direct cell contact possibly mediated through CTLA-4 engagement of B7-1 and
B7-2 on the APC. CD25-mediated depletion of the supportive cytokine IL-2 may also
serve to inhibit immune responses [34]. Given the association of T regulatory cells with
a number of malignancies, including melanoma, lung, ovarian, pancreatic, and breast
cancer, they may play a role in suppressing anti-tumor immune responses and help to
perpetuate the malignancy [35-37].

Immunology in CTCL
In CTCL, the tumor cells lack the co-stimulatory molecules required to trigger an
immune response, which contributes to their ability to evade induction of anti-tumor
immunity and thus, persist and disseminate. Despite the role of DC in providing
proliferative support for the malignancy, DC immunotherapy has demonstrated clinical
benefit in this disease [38, 39].
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We have recently found that passage of cells from CTCL patients through an anti-CD3
magnetic bead column can achieve the simultaneous induction of apoptosis in the
malignant T cell population and differentiation in the monocyte population creating, after
overnight culture, a population of tumor-loaded DC capable of initiating an immune
response in vitro [40]. This column-based method of generating tumor-loaded DC
utilizes the mechanistic principles discovered in extracorporeal photopheresis (ECP),
shown below in Figure 4, the first FDA-approved immunotherapy for cancer [41].
Clinical trials of ECP have shown response rates of 73% in late stage CTCL patients with
an extremely safe side effect profile [42]. ECP has been recently modified by the
addition of an overnight incubation step. The new procedure has been termed
“Transimmunization”, wherein malignant T cells were rendered apoptotic by ultraviolet
A (UVA) light photo-activated 8-methoxypsoralen (8-MOP) and were avidly engulfed by
immature DC, whose transition from monocytes was triggered by the physical
perturbation produced when the cells were passed through the UVA exposure plate of the
ECP apparatus. In Transimmunization, the transitioning DC and the apoptosing
leukocytes are co-cultivated overnight to permit engulfment of the apoptotic cells and
subsequent processing and presentation of the tumor-derived peptides prior to re-infusion
into the host [43].
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Figure 4. Mechanism of extracorporeal photopheresis

We have previously shown that when CTCL cells encounter autologous DC loaded with
high numbers of apoptotic cells, they adopt the phenotype and function of T regulatory
(Treg) cells, expressing high levels of the Treg markers CTLA-4, CD25, and FoxP3, as
well as secreting interleukin-10 (IL-10) and transforming growth factor-β (TBF- β) and
suppressing normal T cell antigen driven secretion of interleukin-2 (IL-2) and interferonγ (IFN-γ) [10]. The induction of Treg from responding CTCL cells may be hindering the
effectiveness of existing immunotherapies for CTCL, and understanding the mechanism
of their induction is paramount to the generation of more effective immunotherapy.
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In these experiments, we sought to determine if the level of apoptotic cell loading
controlled the balance between the development of an anti-tumor immune response and
immunosuppressive Treg cell generation. We found that when lower numbers of
apoptotic cells were processed by DC, a CD8 T cell response could be stimulated while at
higher levels of apoptotic cell up-take by DC we could induce CTCL cell Treg
conversion and inhibit the CD8 T cell response.
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Hypothesis
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Statement of Purpose
In this study, our aim was to further understand the role that antigen dose plays in the
generation of an immunostimulatory response versus a suppressive response. Having
previously demonstrated that autologous DC loaded with large number of apoptotic
CTCL cells can induce tolerance in responding autologous CTCL cells, we sought to
determine if that balance could be shifted toward the generation of immunity by lowering
the dose of apoptotic cells processed by the DC. More specific aims include the favoring
the induction of T regulatory cells and demonstration of Treg specific markers following
co-culture of responding CTCL cells with autologous DC that have engulfed large
numbers of apoptotic cells using the column based method described in the Methods
section In addition, we sought to determine if by lowering the number of apoptotic
malignant T cells engulfed by the DC, could we achieve decreased expression of Treg
markers and increased T cell death and increased perforin expression, indicating
increased cytotoxic effects.
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Materials and Methods
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Methods
Patient Population: Specimens were obtained from a leukapheresis harvest of CTCL
patients (in accordance with the guidelines of the Yale human investigation committee)
undergoing treatment with standard ECP. All patients had advanced disease with clonal
CD4+ T cell populations present in the peripheral circulation as determined by
immunophenotyping with antibodies to the clonotypic variable region of family-specific
TCR or polymerase chain reaction to detect rearrangements of the beta or gamma chain
of the TCR as well as CD8 T cell compartments >10% of the circulating lymphocyte
population.
Cell Isolation: On Day 0, peripheral blood mononuclear cells (MNL) were isolated from
the leukapheresis harvest by centrifugation over a ficoll-hypaque gradient followed by
two washes in RPMI 1640 (Gibco, Gaithersburg, MD) containing 10% AB serum and 2
mM EDTA. An aliquot of the MNL was then isolated, purified, and cultured for
subsequent re-addition on Day 1.

Within this aliquot, CD4+ and CD8+ cells were

column-purified using 40 μl Macs α-human CD4 and CD8 microBeads (Miltenyi
Bioteck, Auburn CA) according to manufacturer’s instructions. The enriched CD4+ and
CD8+ T cells (>97%±0.5% CD4+ and >98%±0.5% CD8+, respectively) were suspended
in RPMI 1640 with 15% autologous serum and IL-2/IL-7 and cultured individually in
separate wells of a 12 well tissue culture plate (Falcon). Another aliquot of the Day 0
isolated MNL was reserved to construct the apoptotic cell and DC dose response curves,
and controls. MNL (2 x 107) from the leukapheresis harvest were incubated with 40 μl
Macs α-human CD3 microBeads following the manufacturer's directions. As previously

17
described [9], CTCL cell binding to CD3 antibody rendered the malignant T cells
apoptotic. As a control, another portion of MNL (2 × 107) was incubated with 40 μl
Macs α-human CD4 microBeads. Following the twenty minute incubation, the cells were
passed through the magnetic bead column, allowing separation of the MNL into either
CD3+ and CD3- fraction or CD4+ and CD4- fractions. The CD3-treated and CD4treated cells were then cultured in 3 ml RPMI 1640 containing 15% AB serum. In some
experiments, increasing doses of CD3-treated cells were added to 105 autologous DC
obtained from the column eluate to create the dose response curves. Controls consisted
of increasing doses of CD4-treated CTCL cells added to 105 autologous DC.
On Day 1, the individually cultured column-purified CD4 and CD8 cells (106) were
added to the CD3-treated apoptotic cell-loaded DC as well as the CD4-treated control
population. After a second overnight culture, the cells were harvested, counted, and
immunophenotyped for markers of T cells, DC, Tregs, and apoptotic cells. I directly
participated in all of these experiments.
Immunophenotyping: In order to monitor enrichment of the purified CD4+ and CD8+
cell populations and to measure the effect of loading DC with differing number of
apoptotic malignant T cells, the cells were stained by two-color immunofluorescence
with a panel of antibodies to monocytes, DC, Tregs, and cytotoxic T cells. Cells (1 × 106)
were incubated with 10–20 μl of fluorochrome conjugated monoclonal antibody for 30
minutes in the dark at 4°C. The antibodies were directly conjugated to fluorescein (FITC)
or phycoerythrin (PE) and included: CD3-FITC (pan T cell); CD4-FITC (inducer T cell);
CD8-FITC (cytotoxic T cell); CD25-FITC (IL2 receptor); CD14-FITC (monocytes);
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HLA-DR-FITC (anti-class II MHC molecule) and CD86-PE (B7.2 co-stimulatory
molecule) and their isotype controls. Cells were washed once and suspended in PBS and
read on a FC500 flow cytometer (Beckman Coulter) within 24 hours.

Combined membrane and cytoplasmic staining was performed following manufacturers
instructions for cell fixation and permeabilization (Intraprep kit, Beckman Coulter).
Antibody combinations included: membrane CD4-FITC/cytoplasmic CTLA4-PE
(inhibitory member of the co-stimulatory family); membrane CD3-FITC/cytoplasmic
CTLA4-PE; membrane CD4-FITC/cytoplasmic FoxP3 (inhibitory transcription factor);
membrane CD3-FITC/cytoplasmic Apo2.7-PE (apoptotic cells); membrane CD8FITC/cytoplasmic perforin-PE (cytotoxic granule); and isotype controls (Beckman
Coulter). Data was analyzed using the CXP software (Beckman Coulter). Cell staining
was conducted by myself, Nianci Wang, and Minjie Wu. All data analysis was done my
myself of Gabe Vasquez with the help of Dr. Carole Berger.
Statistical Evaluation: The expression of DC markers and the induction of a Treg or
cytotoxic T cell response were evaluated statistically in 3 to 5 replicate cultures by the
student’s t test, or if the data was not normally distributed, by the Mann-Whitney Rank
Sum Test using the Sigma Stat analysis program.
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Results
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Results
CTCL Cells Rendered Apoptotic by CD3 Antibody Binding
MNL including monocytes and CTCL cells obtained from a leukapheresis harvest of
CTCL patients were passed through an anti-CD3 magnetic bead column to induce
apoptosis in the antigen-experienced CTCL cells and were then co-cultured with columnpassaged monocytes. As a control, an aliquot of the leukocytes was passed through an
anti-CD4 magnetic bead column, and these viable CTCL cells were cultured with
autologous DC in the same manner as the apoptotic T cells. In Figure 1, apoptosis was
determined by measurement of the co-expression of the membrane T cell marker CD3
and cytoplasmic expression of the early apoptotic marker APO2.7. On primary Day 0
isolation, the percentage of CD3+ cells expressing the apoptotic marker APO2.7 was
0.646%. After overnight culture, 6.96% of the T cell population bound to anti-CD4
antibody-conjugated beads was apoptotic. When lymphocytes were treated with CD3
antibody-conjugated beads, a 2.96-fold increase (P≤ 0.001) in the percentage of apoptotic
T cells was found (20.576%). Thus, CTCL cells treated with anti-CD3 antibody were
rendered apoptotic at a significantly higher percentage and are termed apoptotic CTCL
cells for all future experiments. Those CTCL cells treated with anti-CD4 antibody had a
significantly higher percentage of viable cells and are denoted as viable for the remainder
of the experiments.
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Passage of Monocytes through Magnetic Column Induces DC differentiation
Apoptotic CTCL cells were co-cultured with column-passaged monocytes and markers
known to be up regulated during DC differentiation [43] were analyzed after overnight
culture to determine the ability of passage through the magnetic bead column to drive the
evolution of the monocyte population into DC. Monocyte differentiation into immature
DC was measured by monitoring changes in expression of the monocyte marker, CD14,

Figure 1. Induction of CTCL cell apoptosis by binding to anti-CD3 antibody.
CTCL cells were incubated with either anti-CD4 or anti-CD3 antibody and cultured
overnight with column-passaged monocytes. Apoptosis was determined by measuring
co-expression of the T cell marker, CD3, and the early apoptotic marker, APO2.7.
Statistical analysis performed with student’s t Test.
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and DC markers, class II and CD86. Loss of CD14 expression was revealed by a
decrease in the mean fluorescent intensity (MFI) of the CD14 fluorochrome from primary
isolation on Day 0 followed by co-culture with viable CTCL cells. The maximum
reduction in CD14 MFI was found when column-passaged monocytes were co-cultured
with CTCL cells rendered apoptotic by CD3 antibody (Fig 2A). A 43% reduction of
expression of the monocyte marker CD14 was found in comparison to the level expressed
on monocytes isolated on Day 0 (P≤ 0.005). There was no significant difference in the
reduction in CD14 expression between differentiating DC cultured with viable CTCL
cells or apoptotic CTCL cells. However, the addition of apoptotic tumor cells enhanced
the decrease in CD14 expression while the presence of viable CTCL cells was not as
effective in stabilizing the monocyte to DC conversion.

In addition, expression of class II and CD86 increased significantly (P< 0.017-P< 0.029
respectively) upon co-culture with column-differentiated DC fed apoptotic CTCL cells as
compared to Day 0 controls. Class II expression increased from the level found on Day 0
monocytes to an intermediate increase found on the transitioning immature DC that had
been co-cultured with viable CTCL cells (P≤ 0.011) to the maximal increase seen when
apoptotic CTCL cells (Fig. 2B) were co-cultured with the immature DC. A 5.5-fold
increase in class II expression was found when the DC were fed apoptotic CTCL cells
and compared to the monocytes isolated on Day 0. Expression of the co-stimulatory
molecule CD86 also increased from day 0 to the intermediate increase found on
transitioning immature DC that had been co-cultured with viable CTCL cells (P≤ 0.029)
to the maximal increase in DC fed apoptotic CTCL cells (Fig. 2C). A 25.8-fold increase
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in CD86 expression was found when DC that had engulfed apoptotic cells were
compared to monocytes tested on primary isolation. Therefore, passage of CTCL cells
through an anti-CD3 magnetic bead column and subsequent co-culture of newly
apoptotic CTCL cells with column activated monocytes generated significantly enhanced
DC differentiation. Co-culture of column-activated monocytes with viable CTCL cells
was also effective in generating immature DC but the addition of apoptotic CTCL cells
enhanced the adoption and stabilization of this phenotype.
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Figure 2. DC differentiation from monocytes induced by column passage and apoptotic
CTCL cell loading.
DC and apoptotic CTCL cells were co-cultured following passage of MNL through an
anti-CD3 magnetic bead column. DC differentiation was monitored by measuring
expression of cell surface markers using a flow cytometer gated on the monocyte
population. A. Significant decrease in expression of monocyte marker CD14 was found
on column-passaged monocytes co-cultured with apoptotic CTCL cells when compared
to the level identified on Day 0 monocytes. B. Significant increase in expression of class
II was found on column-passaged monocytes co-cultured with apoptotic CTCL cells
when compared to the level identified on Day 0 monocytes. C. Significant increase in the
expression of CD86 was found on column-passaged monocytes co-cultured with
apoptotic CTCL cells when compared to the level identified on Day 0 monocytes
Statistical analysis performed with student’s t test or Mann Whitney Rank-Sum Test.
NS = not significant.
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Induction of a Treg phenotype.
Freshly purified CTCL cells were incubated overnight with DC that had ingested large
numbers of apoptotic CTCL cells using an apoptotic CTCL cell to DC ratio of ≥ 10:1. A
portion of the responding CTCL cell population adopted the phenotype of T regulatory
cells, expressing the cell surface marker CD25 and the cytoplasmic markers CTLA-4 and
FoxP3. CTLA-4 was up regulated in the cytoplasm of CTCL cells exposed to autologous
DC that had engulfed large numbers of apoptotic cells (Fig. 3C), as compared to the
control group (Fig. 3B) and the primary day 0 isolate (Fig 3A). CTCL cell membrane
expression of CD25 increased upon co-culture with autologous DC that had engulfed
large numbers of apoptotic CTCL cells (Fig 3E) as compared to controls (Fig. 3D). The
viable CTCL cells were also partially activated to express increased membrane CD25
(Fig 3D), but not other markers of Treg conversion (Fig 3B & F). Cytoplasmic
expression of FoxP3 increased 13.9-fold following incubation with autologous DC that
had engulfed large numbers of apoptotic cells (Fig. 3G) as compared to the control
population (Fig. 3F). Thus, by co-culturing freshly purified CTCL cells with autologous
DC that have engulfed large numbers of apoptotic CTCL cells, the responding CTCL
cells adopt a phenotype specific for Treg cells.
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Figure 3. Induction of a T regulatory phenotype in CTCL cells.
A. Untreated Day 0 CTCL cells were stained for co-expression of CD4 on the cell
surface and CTLA-4 in the cytoplasm. DC were fed viable CTCL in ratio of >10:1 or
apoptotic CTCL cells in ratios that exceeded 10 viable (B, D, & F) or apoptotic CTCL
cells (C, E, & G):1 DC and co-expression of: B & C membrane CD4 and cytoplasmic
CTLA4; D & E membrane CD4 and membrane CD25; or F & G cytoplasmic expression
of FoxP3.
We performed a dose response curve by adding increasing numbers of CTCL cells that
had been rendered apoptotic by incubation with CD3-antibody conjugated to magnetic
beads to overnight cultures of column-generated transitioning DC. We found that in the
presence of column-generated DC that had ingested apoptotic CTCL cells, the percentage
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of responding CTCL cells that expressed CTLA-4 increased as the number of apoptotic
cells available for DC ingestion in the co-culture increased (Fig 4A). A dose of 0.3 x 106
apoptotic cells fed to 105 DC induced only 4.88% of the freshly added CTCL cells to
express cytoplasmic CTLA-4. As the dose of apoptotic CTCL cells rose to 1.5 x 106 and
3.0 x 106, the percentage of freshly added CTCL cells expressing CTLA-4 increased to
12.83% and 18.6% respectively. In contrast, as a control, addition of increasing numbers
of viable CTCL cells to the constant number of DC did little to enhance the percentage of
CTCL cells expressing CTLA-4. In addition, as the dose of apoptotic cells fed to a
constant number of DC increased, the percentage of CD4+ T cells expressing FoxP3, the
phenotypic hallmark of Tregs, increased as well (Fig. 4B). At 0.1 x 106 apoptotic cells
fed to a constant number of DC, the percentage of CTCL cells expressing FoxP3 was
1.45%, while a 10-fold increase in the apoptotic cell dose to 1.0 x 106 resulted in a 5.8fold increase to 8.41% of CD4+ T cells expressing FoxP3. This dose-dependent increase
in FoxP3 expression was not seen in the control group where increasing numbers of CD4treated viable CTCL cells were added to a constant number of DC. Therefore, the
generation of CTLA4+/FoxP3+ Treg cells may be controlled, to some degree, by the level
of apoptotic cells fed to the DC.
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Figure 4. Dose-response curve of Treg induction in CTCL cells.
A. Increasing numbers of apoptotic CTCL cells (0.3 x 106, 1.5 x 106, 3.0 x 106) were
added to a constant number of DC (105), co-cultured overnight and used to stimulate
freshly isolated CTCL cells. As controls, increasing numbers of non-loaded DC were
cultured with viable CTCL cells. Freshly isolated CTCL cells were then added and cocultured overnight. The percentage of membrane CD3+/ cytoplasmic CTLA-4+ CTCL
cells was measured by flow cytometry gated on the lymphocyte population. B.
Increasing numbers of apoptotic CTCL cells (0.10 x 106, 0.5 x 106, 1.0 x 106) were added
to 105 DC and co-cultured overnight, followed by addition of 106 purified CTCL cells.
The percentage of membrane CD4+/cytoplasmic FoxP3+ expressing cells was measured
by flow cytometry.
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Treg CTCL cells suppress CD8-mediated perforin expression
As the percentage of CTCL cells that were stimulated to adopt a Treg phenotype
increased, the percentage of CD8+ T cells in co-culture expressing perforin, a granule that
mediates CD8+ effector T cell cytotoxicity [44], inversely decreased (Fig 5). The
percentage of CD3+/CTLA4+ cells was increased from 4.88% to 18.6% (Fig. 5A) in the
presence of DC loaded with increasing numbers of apoptotic cells. Concomitantly, there
was a reduction in the percentage of cells co-expressing CD8/perforin, from 19.68%
down to 9.87% at the highest dose of apoptotic cells used to load the DC. Similarly, as
the percentage of cells expressing CD4+/FoxP3+ increased from 1.45% to 8.41% (driven
by a high dose of apoptotic cell DC loading), the percentage of CD8+ T cells expressing
perforin dropped sharply from 36.69% to 5.58% (Fig. 5B), identifying a possible
threshold of 1-1.5 x 106 apoptotic cells/105 DC required for induction of a Treg
phenotype by the autologous DC. Therefore, when CTCL cells are induced to adopt a
Treg phenotype by co-culturing them with autologous DC that have ingested large
numbers of apoptotic CTCL cells, they display the phenotypic characteristics of Treg, a
conversion that may mediate the reduction in the percentage of CD8 T cells that express
perforin.
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Figure 5. Dose-dependent decrease in CD8-perforin expression as Treg cells increase.
A. As the percentage of membrane CD3+/cytoplasmic CTLA4+ cells increased there
was an inversely related decrease in the number of membrane CD8+/cytoplasmic
perforin+ cells. B. As the percentage of membrane CD4+/cytoplasmic FoxP3+ cells
increased, there was an inversely related decrease in the number of membrane
CD8+/cytoplasmic perforin+ cells.
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Expansion of CD8 T cell compartment following co-culture with autologous DC that
have ingested low numbers of apoptotic cells
We next sought to determine whether controlling the level of apoptotic T cells added to
DC could shift the balance of suppression towards the generation of anti-tumor immunity
by loading autologous DC with low numbers of apoptotic cells. To do this, autologous
DC were fed both a high number of apoptotic CTCL cells (above the demonstrated level
of Treg induction) and a low number of apoptotic CTCL cells, and expansion of the CD8
T cell population was monitored. The percentage of CD8 T cells increased by 83% in the
group of DC fed low numbers of apoptotic T cells (p≤0.042), as compared to control Day
0 samples (Fig. 6A). In addition, the absolute number of CD8 T cells recovered from
overnight culture of column-passaged DC loaded with apoptotic CTCL cells also
increased by 20% when compared to the initial Day 0 level of CD8 T cells (Fig. 6B).
Expansion of the CD8 T cell compartment was greatest when DC were co-cultured with a
lower number of apoptotic T cells, below the threshold for Treg induction, and this
expanded CD8 T cell population might hold the potential to generate anti-tumor
immunity.
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Figure 6. Expansion of CD8 T cell compartment following co-culture with DC loaded
with low numbers of apoptotic CTCL cells.
A. Percentage of CD8+ T cells in co-culture increased significantly upon co-culture
with autologous DC loaded with 0.25 x 106 apoptotic cells. B. The absolute number of
CD8+ T cells increased upon co-culture with DC loaded with 0.25 x 106 apoptotic cells.
Data analyzed using student’s t test. NS = Not significant.
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Increased perforin activity and increased T cell death following loading of
autologous DC with low numbers of apoptotic cells
The expanded CD8 T cell compartment found when freshly purified CD8+ T cells were
co-cultured with autologous DC that had been loaded with low numbers of apoptotic cells
also demonstrated increased perforin activity. The percentage of CD8+ T cells expressing
perforin, the major cytotoxic granule by which effector CD8 cells mediate their antitumor effects, rose from 8.4% (Fig 7A) to 13.8% (Fig 7B) when we lowered the dose of
apoptotic cells fed to the DC. This increase in perforin activity was not seen in the
control population, where viable cells were co-incubated with autologous DC. In
addition, the increased perforin activity translated into significantly increased T cell death
(p≤0.038) in the added CD3+ CTCL T cell population when CD8 T cells were co-cultured
with low numbers of apoptotic cells and DC (Fig 7E). Under these conditions, we found
that 57% more CTCL cells were killed in comparison to the level of cell death obtained
when DC were loaded with high numbers of apoptotic cells and used to prime CD8 T
cells. No significant change in CTCL cell death was noted when viable CTCL cells
were added to the DC. These results indicate that the expanded CD8 T cell population
not only demonstrates increased perforin expression phenotypically, but is also
functionally competent to mediate increased apoptosis in freshly added CTCL cells.
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Figure 7. Enhancement of CD8 T cell response upon exposure to autologous DC loaded
with low numbers of apoptotic CTCL cells.
A - D. DC loaded with 1.0 x 106 and 0.25 x 106 apoptotic malignant T cells stimulated
increased perforin activity in the CD8 T cell compartment, as compared to DC cocultured with 1.0 x 106 and 0.25 x 106 viable CTCL cells. Results are presented as
quadstats measuring the expression of membrane CD8/cytoplasmic perforin as
determined by flow cytometric analysis of the gated lymphocyte population. E.
Increased perforin activity translated into increased CTCL cell death as measured by
membrane CD3/cytoplasmic APO 2.7 staining. Data analyzed using student’s t test. NS
= Not significant.
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Discussion
The development of more effective DC-based immunotherapy has been hampered by a
number of complicating factors, ranging from the length of culture necessary for DC
development in vitro as well as from a lack of knowledge of the most appropriate stage of
DC maturation required for effective anti-tumor vaccination [45]. In addition, the most
appropriate antigen source for DC loading remains to be determined, with a variety of
existing strategies including: purified peptides [46]; tumor-targeted viral vectors [47];
tumor/DC hybrids; apoptotic whole tumor cells; and tumor lysates having been attempted
and resulted in substantial variability in long-term clinical responses [48].

Utilizing a magnetic bead column, we were able to generate potentially immunogenic DC
in a fashion that offers several advantages over existing methodologies: 1) DC generated
in this fashion can be obtained after a single overnight culture, far more rapidly than
existing culture methods which can take up to 7 days; 2) Apoptotic whole cells are used
as a source of tumor antigen, ensuring that the spectrum of CTCL antigenicity is
incorporated into the DC instead of singular known antigens which may not be optimal or
may be lost as the tumor de-differentiates; 3) Passage of monocytes through the column
matrix induces the synchronized differentiation of a large population of monocytes into
DC, allowing for the generation of a more robust source of APC displaying a spectrum of
antigens upon re-injection; 4) The rapidity and ease of manipulating the cellular
subpopulations of apoptotic CTCL cells and antigen-presenting cells allows the ability to
easily optimize the cell populations and added factors in the hope of creating more
effective clinical immunotherapy.
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In these experiments, we sought to further our understanding of the conditions that favor
the induction of Treg cells following exposure to autologous DC co-cultured with large
numbers of apoptotic CTCL cells. The use of the magnetic bead column provides a new
avenue for rapid generation of tumor-loaded DC because the variety of cellular
components inherent in DC differentiation can be titrated to optimize dosing with this
method.

In our studies, CTCL cells were incubated with anti-CD3 antibody prior to passage
through the magnetic bead column, rendering the antigen-experienced malignant T cells
apoptotic, as had been previously demonstrated [38]. In addition, the use of anti-CD4
antibody as a control allowed for separation of viable CD4+ CTCL cells to be used as a
control population while at the same time not altering the CTCL cells in the control group.
The membrane perturbation inherent in monocyte passage through the column matrix
physically stimulates their transition into DC [49]. DC differentiation was measured by
both the reduction of expression of the monocyte marker CD14 and the increased
expression of class II and CD86. In all instances, significant changes in the expression of
these cell markers were found, indicating that the column passaged monocytes were
differentiating into DC and that co-culture of the maturing DC with apoptotic malignant
T cells further stimulated their entry into the DC pathway. Differentiation of monocytes
utilizing membrane stimulation, as in passage through the column matrix, is
advantageous in particular in the setting of cancer immunotherapy since it has been
demonstrated that physical perturbation is one of the more effective means of cross-
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priming phagocytosed peptides into the MHC class I pathway, which is crucial in
generation of a CD8 anti-tumor response [49].

Following the generation of potentially immunogenic DC using the magnetic bead
column, we sought to determine if Treg conversion could be induced. By loading
dendritic cells with large numbers of apoptotic cells, in a ratio of >10 apoptotic cells to 1
DC, we were able to show that CTCL cells could be induced to assume some of the
phenotypic and functional features of Treg cells. These findings correlate with the work
of Berger et al, who has shown that co-culture of freshly purified CTCL cells with
autologous DC loaded with large numbers of apoptotic CTCL cells can induce a Treg
profile in the responding CTCL cell population, one that has phenotypic and functional
characteristics associated with Treg cells [10]. As described earlier, Treg are a subset of
T cells that comprise 5-10% of the peripheral T cell population, and are involved in the
maintenance of peripheral tolerance and prevention of autoimmune disease, regulating
the response to infectious agents, transplanted tissues, and self antigens [29, 30, 50].
Treg are characterized by their ability to suppress immune responses primarily by
inhibiting normal T cell antigen driven proliferation [51, 52]. Treg have been found in
increased numbers in solid tumors and are currently seen as one of the major hurdles to
beneficial clinical responses in existing immunotherapies [53]. Removal of the
suppressive Treg population has been shown to improve the outcome of cancer
immunotherapy in both mouse models and clinical trials in a number of malignancies
[53].
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As the dose of apoptotic CTCL cells fed to a constant number of DC increased,
expression of the Treg-associated markers CTLA-4, CD25, and FoxP3 also increased
concomitantly. In addition, there appeared to be a threshold ratio of apoptotic cell:DC
that corresponded with induction of the Treg phenotype. As the apoptotic cell:DC ratio
increased from 5:1 to 10:1, expression of the hallmark of Treg cells, FoxP3, increased
nearly four fold, indicating that perhaps there may be some internal DC checkpoint
related to the number of processed apoptotic cells that governs the generation of an
immune response versus a suppressive one. While specific mechanisms of this process
remain unclear, we can speculate that perhaps a CD8 T cell response is favored when low
numbers of peptides are presented while induction of an immunosuppressive response
requires a higher antigen burden and presentation of elevated levels of peptides in MHC
class II. In our experiments, the induced phenotypic Tregs also displayed some
functional capabilities, as they were able to suppress CD8-mediated perforin expression
in co-culture; an observation, which if borne out in vivo, may explain some of the failures
in generating anti-tumor immunity with existing immunotherapies. These findings are in
concert with our previous studies which demonstrated that cultured CTCL cells can be
stimulated to assume a Treg phenotype and function suppressing normal T cell driven
immune responses when exposed to DC that have ingested apoptotic cells [4]. In our
present studies, we demonstrate that, in addition, freshly isolated CTCL cells can be
driven to adopt a Treg phenotype by overnight exposure to DC loaded with large
numbers of apoptotic cells.
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By establishing that Treg cells could be rapidly generated using this method, we then
sought to determine if that delicate balance between the DC and surrounding numbers of
apoptotic cells could be shifted in the other direction, towards stimulating a more
vigorous immune response. By lowering the dose of apoptotic cells processed by a
constant number of DC, we were able to induce significant expansion of the CD8 T cell
compartment. This expanded CD8 T cell compartment not only contained a greater
percentage of perforin expressing cells but also mediated increased T cell death in the
added CTCL cell population. In terms of existing immunotherapies, these findings hold
major clues into possible mechanisms for tumor survival following treatment. If too
aggressive an attempt is made at killing tumor cells in hopes of loading DC with large
number of tumor antigens, it may lead to Treg generation and suppression of the desired
immune response. A considerable body of literature exists supporting the idea that the
difference between the DC’s ability to induce tolerance or mediate immunity may be
determined by its persistent exposure to antigen. [54, 55] In our experiments, the DC that
were exposed to larger numbers of apoptotic cells and hence had more persistent antigen
exposure induced suppression of the CD8 T cell population. These findings support
earlier work and help to reinforce the role of apoptosis in the induction of
immunosuppression. [28, 56]

A better understanding of the role of Treg cells in immunotherapy is crucial because
while they hamper the effectiveness of cancer immunotherapy [53], Treg may be of great
value for the therapy of autoimmune disease and transplantation tolerance. [30, 57] The
ability to use rapid methods such as the magnetic bead column allows for optimization of
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existing methodologies so that we can improve our understanding of apoptotic T cell and
DC interactions, with the goal of creating more effective cancer immunotherapy.
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